X Chen, Y Hu, Z Cao, Q Liu, Y Cheng - Frontiers in immunology, 2018 - frontiersin.org
It has been suggested that cytokine-mediated inflammation plays a key role for the onset and/or development of neurodegenerative diseases including Alzheimer's disease (AD) …
I Savelieva, S Fumagalli, RA Kenny, S Anker… - Europace, 2023 - academic.oup.com
There is an increasing proportion of the general population surviving to old age with significant chronic disease, multi-morbidity, and disability. The prevalence of pre-frail state …
KG Yiannopoulou… - Therapeutic advances in …, 2013 - journals.sagepub.com
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized …
JS Lin, E O'Connor, RC Rossom… - Annals of internal …, 2013 - acpjournals.org
This article has been corrected. The original version (PDF) is appended to this article as a supplement. Background: Earlier identification of cognitive impairment may reduce patient …
R Howard, R McShane, J Lindesay… - … England Journal of …, 2012 - Mass Medical Soc
Background Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment …
BACKGROUND: Studies suggest that inflammation is involved in the neurodegenerative cascade leading to Alzheimer's disease (AD) pathology and symptoms. This study sought to …
The prescribing cascade revisited The prescribing cascade revisited Lancet. 2017 May 6;389(10081):1778-1780. doi: 10.1016/S0140-6736(17)31188-1. Epub 2017 May 4. Authors Paula A Rochon 1 , Jerry …
Alzheimer's disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As …